IMA vs PSA · rev $9.2M vs rev $4.82B
ImageneBio, Inc. (IMA) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
IMA currently screens at market cap $64.7M. PSA currently screens at market cap $0.
Not investment advice. Open the IMA and PSA stock pages for the full models.
Not investment advice.